secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001437749-23-031971
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva reports Q3 loss of $10.5M; Phase 3 brilaroxazine trial meets all endpoints
--------------------------------------------------------------------------------

- Phase 3 RECOVER trial met primary endpoint: 10.1-point PANSS reduction for 50 mg brilaroxazine vs placebo at week 4 (p<0.001).
- Net loss for Q3 2023 of $10.5M ($0.44/share) vs $3.5M loss ($0.18/share) in Q3 2022.
- Cash of $5.0M as of Sep 30, 2023, down from $18.5M at Dec 31, 2022.
- Anticipated milestones: OLE data Q4 2024; RECOVER-2 initiation Q1 2024; NDA submission 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/0001437749-23-031971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/rvph20231109c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer